RDTI & Australian R&D Context — Glossary¶

← Back to glossary index

The Australian R&D Tax Incentive (RDTI), the regulatory framework around it, and the documentation concepts that drive a defensible RDTI claim. Particularly important for any biotech with Australian operations or considering an Australian footprint — and for any conversation referencing Flusso's native RDTI module.

Terms covered:

R&D Tax Incentive (RDTI)
43.5% refundable tax offset
Eligible R&D activity
Core Activity vs Supporting Activity
Knowledge Area (KA)
AusIndustry / DISR / ATO
Tax Promoter Penalty regime
Aggregated turnover threshold
R&D Tax Incentive registration vs. claim

R&D Tax Incentive (RDTI)¶

Definition. An Australian Government program that provides a tax offset to eligible companies conducting eligible R&D activities. Administered jointly by AusIndustry (within the Department of Industry, Science and Resources — DISR) and the Australian Taxation Office (ATO). The largest single source of public R&D support in Australia.

In practice. The RDTI has two tiers:

Refundable offset (43.5%) — for companies with aggregated turnover under $20M; the offset is refundable as cash even if the company has no taxable income (the typical case for early-stage biotechs)
Non-refundable offset (38.5% / 46.5%) — for companies with aggregated turnover at $20M or above; the offset reduces tax payable but is not refundable as cash

The claim process:

Register R&D activities with AusIndustry within 10 months after the end of the financial year
Claim the tax offset through the company's annual tax return to the ATO
Maintain contemporaneous evidence of eligible activities and expenditure (this is the operationally critical piece)

Why it matters. For a small-cap biotech with significant R&D spend and no taxable income, the RDTI is often the largest single cash inflow other than equity raises and partnership milestones. Recovering 43.5% of eligible R&D spend as cash refund is materially significant.

Where Flusso fits. Flusso's RDTI module provides continuous evidence capture aligned to RDTI eligibility framework — Knowledge Areas, Core Activities, Supporting Activities, contemporaneous documentation, defensible audit trail. Designed under the Tax Promoter Penalty regime so the evidence chain holds up under AusIndustry / ATO review.

43.5% refundable tax offset¶

Definition. The tier of the RDTI offset available to companies with aggregated turnover under AUD $20M. Refundable means it is paid out as cash even when the company has no taxable income — the typical position of early-stage biotechs. The headline rate that drives RDTI economic significance for early-stage companies.

In practice. For an early-stage biotech with no profit:

$10M of eligible R&D expenditure → ~$4.35M cash refund
$5M of eligible R&D expenditure → ~$2.175M cash refund
$2M of eligible R&D expenditure → ~$870K cash refund

The refund typically arrives in the financial year following the claim.

The non-refundable tier rate (for companies above the $20M aggregated turnover threshold) is calculated based on the company's R&D intensity (R&D as a fraction of total expenditure):

Lower intensity (<2%): 38.5% offset
Higher intensity (≥2%): 46.5% offset

Why it matters. The 43.5% rate is one of the most generous R&D incentives globally and has been a major driver of Australia's biotech ecosystem. For pre-revenue biotechs, it functions as a recurring non-dilutive cash injection.

Eligible R&D activity¶

Definition. Activities that meet the legislative definition for RDTI eligibility. The Income Tax Assessment Act 1997 defines eligible R&D activities as either Core Activities or Supporting Activities, with strict tests for each.

In practice. A Core Activity is one where:

The outcome cannot be known or determined in advance on the basis of current knowledge
It is conducted for the purpose of generating new knowledge
It involves a systematic progression of work that proceeds from a hypothesis to experiment, observation, evaluation, and logical conclusions

A Supporting Activity is one that has a direct, close, and immediate relationship to a Core Activity.

Common ineligible activities (worth understanding because they're easy to misclassify):

Routine testing or analysis
Market research, sales promotion
Quality control
Trial production runs
Software development for internal use (subject to specific tests)

Why it matters. Eligibility is the gating question for every RDTI claim. Misclassification is the primary cause of AusIndustry adverse findings on review or audit. Robust contemporaneous evidence supporting eligibility classification is what protects a claim under scrutiny.

Where Flusso fits. Flusso's RDTI module structures activity decomposition aligned to the eligibility framework — making the Core/Supporting distinction explicit and the evidence supporting each activity continuous and defensible.

Core Activity vs Supporting Activity¶

Definition. The two categories of eligible R&D activity under RDTI:

Core Activity — experimental activity whose outcome cannot be determined in advance, conducted for the purpose of generating new knowledge through systematic experimentation
Supporting Activity — activity that supports a Core Activity with a direct, close, and immediate relationship

In practice. In a clinical trial context, examples often look like:

Core Activity — designing and executing a Phase 1 dose-finding study to determine the optimal dose of a novel mechanism-of-action agent (the outcome — what dose works — cannot be known in advance)
Supporting Activity — manufacturing the investigational product for that Phase 1 study, building the EDC database for that study, regulatory submissions for that study

The distinction matters because the eligibility tests differ — Core Activities must meet the systematic-experimentation bar; Supporting Activities must demonstrate the direct-and-immediate-relationship test.

Why it matters. Misclassification — typically claiming Supporting Activities as Core, or claiming non-experimental work as Core — is the most common RDTI eligibility failure. Per Flusso's internal authoring boundary (Stephen Carroll-blessed regulatory line), AI may author Knowledge Areas but Core/Supporting Activities are human-only edit — a deliberate defensibility constraint under the Tax Promoter Penalty regime.

Where Flusso fits. The activity decomposition in Flusso's RDTI module enforces the Core/Supporting distinction at the data model level. AI-assisted Knowledge Area authoring with human-only Core/Supporting Activity edit rights is the regulatory-defensibility design choice.

Knowledge Area (KA)¶

Definition. A structured grouping of related R&D activities, hypotheses, experiments, and findings within an RDTI claim. Used to organise the evidence chain supporting eligible activities and to make the activity narrative coherent and defensible.

In practice. A typical Knowledge Area might cover:

A specific scientific question (e.g., "optimisation of conjugation chemistry for masked ADC platform")
A hypothesis under test
The series of experiments designed to test the hypothesis
The evidence generated
The conclusions and implications for further work

A claim typically contains several Knowledge Areas; each KA may contain multiple Core Activities and their associated Supporting Activities.

Why it matters. The Knowledge Area is the unit at which AusIndustry reviewers assess the systematic-experimentation narrative. A well-structured KA tells a coherent scientific story; a poorly-structured KA invites scepticism.

Where Flusso fits. Knowledge Areas are first-class entities in Flusso's RDTI module. AI-assisted authoring helps draft KA narratives from contemporaneous evidence; human-only Core/Supporting Activity edit rights preserve the defensibility boundary. Cross-references to evidence (clinical data, manufacturing records, experimental reports) are tracked in the source-document linkage layer.

AusIndustry / DISR / ATO¶

Definition. The three Australian Government bodies that administer the RDTI:

AusIndustry — the program delivery arm within DISR; assesses R&D activity registrations and conducts compliance reviews
DISR (Department of Industry, Science and Resources) — the parent department for AusIndustry
ATO (Australian Taxation Office) — administers the tax offset itself; assesses R&D expenditure claims and conducts ATO-led reviews

In practice. A typical RDTI lifecycle:

Activity registration — submitted to AusIndustry within 10 months after financial year end
Tax offset claim — submitted to ATO via the company's tax return
AusIndustry review (potentially) — assessment of activity eligibility
ATO review (potentially) — assessment of expenditure eligibility
Adverse finding (potentially) — partial or full rejection of the claim, with potential interest and penalty consequences

The two reviews are conceptually distinct — AusIndustry reviews the activities (was it eligible R&D?); ATO reviews the expenditure (was it legitimately incurred and apportioned?).

Why it matters. Both bodies can review independently, and an adverse finding from either can result in claw-back of the offset plus interest and penalties. Robust contemporaneous evidence is the primary defence against either review.

Tax Promoter Penalty regime¶

Definition. A statutory framework under Division 290 of the Tax Administration Act 1953 that imposes penalties on individuals or entities that promote tax exploitation schemes. Has become particularly important in the RDTI context following ATO concerns about claim aggressiveness in some advisory practices.

In practice. The Tax Promoter Penalty regime targets:

Advisers who promote schemes with aggressive interpretations of RDTI eligibility
Software platforms or services that facilitate non-compliant claims
Marketing of "guaranteed" RDTI outcomes that misrepresent the eligibility framework

Penalties can be substantial (up to AUD $1.36M for individuals, $6.78M for entities in 2026 indexation; pecuniary penalties calculated as the greater of a fixed amount or a multiple of fees received).

Why it matters. Any platform supporting RDTI claims operates under this regime. Claims-supporting infrastructure must be designed with defensibility in mind — not just claim maximisation. This is the why behind Flusso's design choice to make AI an author for Knowledge Areas only, with Core/Supporting Activities as human-only edit.

Where Flusso fits. Flusso's RDTI module is designed under explicit Tax Promoter Penalty regime considerations. The AI authoring boundary is the most concrete expression of this. The continuous evidence capture model, contemporaneous documentation, and clear activity decomposition all serve defensibility under review.

Aggregated turnover threshold¶

Definition. The financial threshold ($20M for the 2025-26 income year) that determines which RDTI tier a company falls into. Aggregated turnover includes the company's own turnover plus the turnover of "connected" or "affiliated" entities, calculated under specific tax-law definitions.

In practice. Companies under the threshold get the refundable 43.5% offset. Companies at or above get the non-refundable offset (38.5% or 46.5% depending on R&D intensity).

For a small-cap biotech, aggregated turnover is typically straightforward (the biotech's own revenue, often near zero). For a biotech with a parent company or affiliated entities (e.g., a global biotech with an Australian subsidiary), the aggregation calculation can be more complex and may push the entity over the threshold even if its standalone turnover is small.

Why it matters. The threshold is the difference between a refundable cash offset (always valuable) and a non-refundable offset (only valuable if there's tax to offset). Crossing the threshold is a major economic event for an early-stage biotech.

Related: 43.5% refundable tax offset

R&D Tax Incentive registration vs. claim¶

Definition. Two distinct steps in the RDTI lifecycle that are sometimes conflated:

Registration — submission to AusIndustry of the R&D activities conducted in a financial year. Required before any tax offset can be claimed. Due within 10 months of financial year end.
Claim — the tax offset claimed through the company's annual tax return submitted to the ATO. The financial mechanism that produces the cash offset.

In practice. Registration must precede claim — but claim can occur in any tax return lodged after registration, including amended returns within the standard amendment window.

Why it matters. The distinction matters operationally because the timeline obligations are different (10 months for AusIndustry registration; standard ATO lodgement timelines for the tax return). It also matters because the two bodies can review independently — AusIndustry reviews registration, ATO reviews the claim.

← Back to glossary index